Evidence map›Paper›PMID 40429944›Full record

ArticleInternational journal of molecular sciences2025

Hemoglobin Disorders Associated with Neurological Impairment: First Report of ATR-X Syndrome and Recessive Congenital Methemoglobinemia Type II in Tunisia.

Houyem Ouragini, Emna Bouatrous, Manel Kasdallah, Sonia Nouira, Hamza Dallali, Samia Rekaya, Dorra Chaouachi, Monia Ouederni, Samia Menif

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Houyem OuraginiLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.ORCID 0000-0003-2427-2804
Emna BouatrousLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Manel KasdallahLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Sonia NouiraLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Hamza DallaliLaboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Samia RekayaLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Dorra ChaouachiLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Monia OuederniLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.
Samia MenifLaboratory of Molecular and Cellular Hematology, LR16IPT07, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis 1002, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemoglobin disorders are among the most common inherited diseases worldwide. Their clinical manifestations range from anemia to more severe forms associated with neurological impairments. These complications can result as secondary consequences of the disease's clinical manifestations or be directly linked to genetic mutations. In this study, we present two families with neurological impairments who were referred to us for complementary hematological and biochemical analyses. Complete blood count, methemoglobin level, and methemoglobin reductase activity were assessed. Molecular analyses were performed using whole-exome sequencing, and the segregation of the identified mutations was confirmed with direct sequencing. Their pathogenicity and conservation were evaluated using various bioinformatics tools. Clinical and hematological findings suggested X-linked alpha-thalassemia/impaired intellectual development syndrome in the first family and recessive congenital methemoglobinemia type II in the second. This was confirmed by the identification of pathogenic mutations

Indexed as

Genetic Diseases, X-LinkedMethemoglobinemiaNervous System DiseasesX-Linked Intellectual DisabilityX-linked Nuclear ProteinAdultalpha-ThalassemiaChildChild, PreschoolCytochrome-B(5) ReductaseExome SequencingFemaleHumansMaleMutationPedigreeATRX protein, humanCYB5R3 protein, humanCytochrome-B(5) ReductaseX-linked Nuclear ProteinATR-X syndromediagnosismutationneurological diseaserecessive congenital methemoglobinemia type IIWES

Identifiers

PMID40429944
PMCPMC12112465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.